Table 3. Multivariate Cox’s proportional hazards model analyses of survival and bone metastasis (BMT).
HR | 95% CI | P-value | |
DFS | |||
Nucleolin | |||
CD31loNCLlo | 1.00 | ||
CD31hiNCLlo | 1.462 | 0.790∼2.706 | 0.226 |
CD31hiNCLhi | 2.414 | 1.346∼4.331 | 0.003 |
Stage | |||
Stage I | 1.00 | ||
Stage III | 4.265 | 2.420∼7.515 | <0.001 |
OS | |||
Stage | |||
Stage I | 1.00 | ||
Stage II | 4.312 | 1.919∼9.688 | <0.001 |
Stage III | 6.755 | 3.162∼14.431 | <0.001 |
BMT | |||
Nucleolin | |||
CD31loNCLlo | 1.00 | ||
CD31hiNCLlo | 1.342 | 0.503∼3.579 | 0.556 |
CD31hiNCLhi | 1.578 | 0.621∼4.009 | 0.338 |
Stage | |||
Stage I | 1.00 | ||
Stage II | 5.292 | 1.396∼20.055 | 0.014 |
Stage III | 9.497 | 2.727∼33.066 | <0.001 |